Kornimate/medical-research-clean huggingface dataset:
identification of cutaneous and blood biomarkers predictive of response to systemic treatments during chronic inflammatory skin diseases

Conditions: Atopic Dermatitis; Psoriasis; Hidradenitis Suppurativa; Lichen Planus; Cutaneous Lupus; Dermatomyositis; Cutaneaous Scleroderma; Neutrophilic Dermatosis; Cutaneous Granulomatosis; Active Leprosy

Summary: chronic inflammatory skin diseases constitute a heterogeneous group of pathologies. they affect the skin but also other organs (joints, lungs, muscles, etc.). their prognosis and response to treatments is extremely variable. the discovery of prognosis factors will help to precisely guide the treatment regimen and its intensification based on individual markers. the identification of new therapeutic targets is essential to develop new innovative treatments for inflammatory skin diseases. the main objective is to identify new cellular or molecular prognostic factors associated with treatment response at 1 year in inflammatory skin diseases. the secondary objectives are a better understanding of the pathophysiology of chronic inflammatory skin diseases, the identification of new cellular, molecular and microbiological prognostic factors associated with the clinical state after 10 years of evolution and the identification of prognostic markers of drug toxicity.


Eligibility criteria:
inclusion criteria: patients: * age\>18 years * informed consent signed by the patient * diagnosis of moderate to severe chronic inflammatory skin disease (iga score 3 or 4) including: atopic dermatitis, psoriasis, hidradenitis suppurativa, lichen planus, cutaneous lupus, dermatomyositis, cutaneous scleroderma (=morphea), neutrophilic dermatosis, cutaneous granulomatosis * or diagnosis of active leprosy (tuberculoid, lepromatous, reversion type 1, reversion type 2, hypersensitivity type 3), excluding pure neurological leprosy. classification into 5 stages according to the ridley and jopling classification \[1\], reversion reaction (type 1 reaction) and leprous erythema nodosum (type 2 reaction). healthy controls : * age\>18 years * plastic surgery patients who have had any type of surgery resulting in healthy skin remnants * informed consent signed by the patient * absence of known cutaneous or systemic inflammatory disease. exclusion criteria: * under guardianship or curatorship * pregnant or breastfeeding woman * lack of affiliation with a social security system * systemic treatment in progress or received less than 3 months ago.
virtual reality videos in improving bowel preparation quality of colonoscopy

Conditions: Patient Compliance; Colo-rectal Cancer

Summary: colonoscopy is the most important method to screen for colorectal cancer and precancerous lesions, whose efficacy is closely related with the quality of bowel preparation, requiring consuming purgatives and restricting the diet. compliance to bowel preparation is highly dependent on patient education. in most cases, such education is offered only once at the time of colonoscopy scheduling by either oral or written instructions. however, about one in fourth patients still cannot achieve satisfactory bowel preparation quality. various methods, including booklet, telephone or message reminders, smartphone applications, social media, online videos, have been used to aid patient education and prove effective. these methods can increase patient activation, which is an independent factor related to bowel preparation quality. virtual reality(vr) videos are used in this study, giving patients direct impressions of colonoscopy. this study aims to explore whether vr videos can increase patient adherence and experience, as well as improve bowel preparation quality, compared with conventional patient education methods.


Eligibility criteria:
inclusion criteria: * outpatients indicated for elective colonoscopy: 1) for screening purposes: asymptomatic patients with average or high risk for colorectal cancer\[1\]; 2) for diagnostic purposes: patients presented with abnormal imaging or lower gastrointestinal symptoms including bloody stool, chronic diarrhea and abdominal pain\[2\]. * never undergo colonoscopy before. * age 18-75 years. * written informed consent. exclusion criteria: * history of bowel surgery * comorbidity disorder (ascites, congestive heart failure, chronic renal failure, coronary vessel disease within the last 6 months) * drug use (eg, constipation drugs, laxatives, or anti-diarrheal agents) * pregnancy * severe constipation (\<3 bowel movement/week) * inflammatory bowel disease * unable to watch vr videos (eg, blindness)

Keywords: bowel preparation colonoscopy virtual reality patient education
adaptation of the questionnaire "regarding patient's quality of life with mastocytosis" in the french language

Conditions: Cutaneous Mastocytosis; Indolent Systemic Mastocytosis

Summary: mastocytosis is a heterogeneous rare disease. a 27-item questionnaire to assess the quality of life of patients with cutaneous/ indolent systemic mastocytosis was developed in the german language and validated in the english language in 2015. the team of the university charité berlin and the company moxie - intellectual proprietor of the questionnaire - proposed the use of the recommendations of baiardini et al. 2010, for linguistic adaptation of this questionnaire in other languages.

the first two steps of the program of linguistic translation have already been carried out under the direction and supervision of teams from charité university, berlin and moxie company. the result of these two steps is a secondary version of the mc-qol questionnaire in french. the last step of this adaptation process in the target language (french, france) needs to be carried out and it is the subject of this study. the objective of this study is the french language adaptation of the mc-qol questionnaire in adult patients with indolent cutaneous and / or indolent systemic mastocytosis. during this study, the second version of the mc-qol questionnaire in french will be evaluated on 10 adult patients, with cutaneous and / or indolent systemic mastocytosis and native in the french language. the comprehension tests will be carried out by means of the structured interviews during which the investigator will ask if the patient has had difficulties to understand the recommendations, the questionnaires, will verify the interpretation of all the items and the understanding of each word by the patient. in case of problems, the investigator will propose and / or test translation alternatives, or will ask the patient to propose alternatives. revisions to the second version of the mc-qol questionnaire in french will be done to rectify the problems identified in the conceptual equivalence. the result will be a third french version of the mc-qol questionnaire, which will be the final version. a report on the interviews will be written in english: it will describe the number of respondents, their age, the time required to complete the questionnaire, the difficulties encountered, the solutions suggested and retained and how the third version of the questionnaire was produced.

Eligibility criteria:
inclusion criteria: * adult, native french patient with cutaneous or indolent systemic mastocytosis and follow-up at ceremast, toulouse * patient having given his agreement of non-opposition exclusion criteria: * minor patient * patient with other forms of mast cell pathology except cutaneous and / or indolent systemic mastocytosis * patient with no mast cell pathology * french non-native patient * patient in detention or under guardianship * patient not affiliated with social security

Keywords: cutaneous mastocytosis indolent systemic mastocytosis quality of life questionnaire in mastocytosis patient
pilot study of reduced intensity haematopoietic stem cell transplantation in patients with poor risk myelodysplastic syndrome (mds) and acute myeloid leukaemia (aml) utilising conditioning with fludarabine, busulphan and thymoglobulin

Conditions: Myelodysplastic Syndromes; Leukemia, Myeloid, Acute

Summary: the purpose of this study is to determine the safety and feasibility of conditioning with fludarabine, busulphan and thymoglobuline in patients with myelodysplastic syndrome (mds), myelodysplastic/myeloproliferative disorders (mds/mpd) or acute myeloid leukaemia (aml) undergoing haematopoietic stem cell allograft with granulocyte colony-stimulating factor (g-csf)-mobilised peripheral blood stem cells (pbsc) (or bone marrow) from hla compatible sibling donors.


Eligibility criteria:
inclusion criteria: patient selection 1. availability of a hla compatible sibling donor 2. age \>18 years 3. myelodysplastic syndromes with ipss intermediate-2 or high. 4. poor risk acute myeloid leukaemia, de novo or transformed from mds 5. ineligibility for standard conditioning allograft due to age or co-existing morbidities donor selection 1. related donors compatible for hla-a, b, c, drb1 and dqb1 by molecular typing. exclusion criteria: patient selection 1. cardiac insufficiency requiring treatment or symptomatic coronary artery disease. 2. hepatic disease, with ast \> 2 times normal. 3. severe hypoxaemia, po2 \< 70 mm hg, with decreased dlco \< 70% of predicted; or mild hypoxemia, po2 \< 80 mm hg with severely decreased dlco \< 60% of predicted. 4. impaired renal function (creatinine \> 2 times upper limit of normal or creatinine clearance \< 50% for age, gender, weight). 5. patients who have received previous treatment with thymoglobuline 6. hiv-positive patients. 7. female patients who are pregnant or breast feeding due to risks to foetus from conditioning regimen and potential risks to nursing infants. 8. life expectancy severely limited by diseases other than mds or mpd. 9. serious concurrent untreated infection 10. patients with limited life expectancy for other reasons 11. serious psychiatric/ psychological disorders 12. absence of /inability to provide informed consent donor selection 1. age \>75 years, unless independently assessed to be medically fit to donate 2. donors who for any reason are unable to tolerate the leukapheresis procedure and cannot undergo anaesthesia for marrow harvest. 3. donors who are hiv-positive, or hepatitis b or c pcr positive. 4. donors who are medically unsuitable to donate

Keywords: myelodysplastic syndromes leukemia, myeloid, acute haematopoietic stem cell transplantation fludarabine busulphan thymoglobuline
effect of ci on prognosis in the elderly patients with acs

Conditions: Acute Coronary Syndrome; Cognitive Impairment; Elderly

Summary: this study aims to investigate the incidence and characteristics of cognitive impairment(ci) in the elderly patients with acute coronary syndrome (acs), and to determine whether ci are predictive of the prognosis of major adverse cardiovascular events (mace) and mortality.


Eligibility criteria:
inclusion criteria: * ≥65yr * confirmed acs diagnosis （include unstable angina, st-segment elevation myocardial infarction and non st-segment elevation myocardial infarction） * fulfilled mmse or moca * patients agreed and provided informed consent exclusion criteria: * type 2 myocardial infarction and acute nonischemic myocardial injury * past history of malignant tumors * past history of stroke or dementia * hepatic insufficiency (alt\>8uln or alt\>3uln and tbil\>2uln) * renal insufficiency (gfr\<15 ml/min/1.73m2)
effect of topical trimebutine on pain after hemorrhoidectomy

Conditions: Hemorrhoids

Summary: trimebutine acts through smooth muscle relaxation. it is presumed that the topical application of trimebutine after hemorrhoidectomy may help relieve pain after the procedure by relaxing the internal anal sphincter spasm.

a randomized trial will be carried out to investigate the effect of trimebutine on pain after milligan-morgan hemorrhoidectomy. trimebutine relaxes the internal anal sphincter spasm which usually occurs after excisional hemorrhoidectomy.

Eligibility criteria:
inclusion criteria: * patients of both genders aging between 18-70 years with grade iii/vi internal hemorrhoids will be included exclusion criteria: * patients with grade i/ii internal hemorrhoids or external hemorrhoids. * patients with associated anorectal pathology such as anal fissure, anal fistula, rectal prolapse, neoplasm, solitary rectal ulcer, and inflammatory bowel diseases.\\ * patients with recurrent hemorrhoids after previous surgery.
buparid/pari sinus versus budes® nasal spray in the therapy of chronic rhinosinusitis with polyposis nasi

Conditions: Rhinosinusitis; Chronic Polyposis

Summary: the study should create data for the selection of a clinically relevant primary endpoint to assess the efficacy and safety of buparid/pari sinus as compared to budes nasal spray in the therapy of chronic rhinosinusitis (crs) with polyposis nasi in adult patients. ideally, the selected parameter should allow a correlation between an objective methodology and the clinical outcome of the study patients.


Eligibility criteria:
inclusion criteria: * patient with confirmed diagnosis of chronic rhinosinusitis (crs) with polyposis nasi grade i-iii * patient with a pnif of \> 7 l/min separated for left and right side of the nose * patient's written informed consent * male or female,\>= 18 years of age * patient is able to undergo nasal therapy without restrictions * capable of understanding the purpose and risk of the clinical trial * female patients with childbearing potential must have a negative urine pregnancy test prior to first imp administration * patient has completed correctly the diary during the wash-in phase exclusion criteria: * patients with cystic fibrosis * patients with polyposis nasi grade iv * patients with prior sinonasal surgery (exemption: polypectomy) * patients with primary ciliaritis * pregnant or breastfeeding women * patients with suspected active upper airway infection * receipt of an investigational drug as part of a clinical trial within 4 weeks prior to first administration of imp * drug or alcohol abuse * end-stage malignancies * known hypersensitivity to budesonide * patients with oral steroid therapy within the last 4 weeks * patients with frequent epistaxis (\> 2 per month)

Keywords: crs polyposis
scs stimulation clamp to assess impact of stimulation on glucose metabolism

Conditions: Spinal Cord Stimulation (SCS); Blood Glucose Metabolism; Euglycemic Hyperinsulinemic Clamp

Summary: in 1967 spinal cord stimulation (scs) for the treatment of chronic neuropathic pain was established. today various pain syndromes like the failed back surgery syndrome (fbss), the complex regional pain syndrome (crps), ischemic pain or phantom limb pain are treated with scs. the development of this technique based on the so called "gate control theory" which states that stimulation of the mechanosensitive aβ fibers suppresses the transmission of pain stimuli via the pain-sensitive c fibers to the brain in the spinal cord. conventional scs consists of periodically emitted tonic stimuli with a frequency between 30 and 120 hz. during implantation, the electrodes are placed in the epidural space in such a way that the paraesthesia caused by nerve stimulation covers the painful area (dermatome), thus relieving the pain. in 2010 de ridder et al. published an article presenting the so called "burst stimulation" where series of high-frequency impulses are released at defined time intervals (frequency: 40 hz with peaks of 500 hz per volley). compared to the tonic scs the burst technique is more effective and in most cases no paraesthesia is reported. however, potential effects of scs stimulation on other organ systems have only been insufficiently examined.especially possible effects of scs on the glucose metabolism has not been investigated so far. however, it is important to investigate a possible effect for two reasons: scs could cause severe hypoglycemia which must be avoided. furthermore, if scs affects blood sugar levels, it is also of interest what mechanisms are involved and how this knowledge can be used to control elevated blood glucose levels. the present study is a pilot. the investigators want to examine possible effects of scs therapy on blood glucose metabolism. therefore hyperinsulinemic euglycemic clamps with an insulin infusion of 1mu / kg body weight per minute are performed. during the clamp the investigators apply different scs techniques in a randomly order. insulinsensitivity is determined at different time points.


Eligibility criteria:
inclusion criteria: * understand and voluntarily sign an informed consent document prior to any study related assessments/procedures. * hba1c \< 6,0% * state after implantation of an neuromodulation device * clinical routine blood parameters within the normal ranges exclusion criteria: * diabetes mellitus * acute diseases such as infections (e.g.) within the last four weeks * hb \< 13 g/dl * anamnestic heparin-induced thrombocytopenia * any neurologic or psychiatric disease
functional magnetic resonance imaging (fmri) exploration of neurocognitive processes involved in food addiction (fa) in obese patients: towards new phenotypic markers for an optimized care pathway

Conditions: Obesity

Summary: identification of the cerebral fmri phenotype of obese patients with fa in cognitive task context based on food choice making

obesity is a worldwide epidemic associated with many complications. the treatment of obesity is a failure if it does not take into account eating disorders. among them, food addictions seem to be frequent among obese patients. clinical diagnosis and therapeutic approaches depend on presence of these fa. moreover, eating disorders are associated with visible brain abnormalities in fmri but the cerebral fmri phenotype of fa is not known.

Eligibility criteria:
inclusion criteria: * female * right-handed * grade 1 and 2 obesity * aged between 20 and 50 * no other addictions including smoking * no contraindications to fmri * affiliated to french social security * having given a written informed consent exclusion criteria: * abdominal circumference + upper limbs along the body \> 200cm * addiction to alcohol or other psychoactive substances * daily smoker * sleep apnea syndrome paired * psychotic psychiatric disorders * history of bariatric surgery * medical care in the nutrition unit * inability to comprehend or complete questionnaires * pregnant or breastfeeding woman * persons subject to major legal protection (safeguarding justice, guardianship, trusteeship), persons deprived of liberty.

Keywords: obesity food addictions functional magnetic resonance imaging (fmri) metabolomics
ruboxistaurin in new york heart failure classification iii-iv patients

Conditions: Heart Failure

Summary: this study evaluates the effect of ruboxistaurin for its safety, tolerability, and effectiveness in treating adult patients with heart failure. patients will receive 1 dose of oral ruboxistaurin.

ruboxistaurin is a drug initially developed for treatment of diabetic peripheral retinopathy. the proposed indication for ruboxistaurin in this study is the treatment of adult patients with new york heart failure association (nyha) class iii-iv heart failure. ruboxistaurin is a protein kinase c-alpha (pkc-alpha) inhibitor and thus will produce an inotropic effect in the heart which holds the potential to improve cardiac function.

Eligibility criteria:
inclusion criteria: 1. male or female, 30-75 years of age, inclusive 2. nyha class iii-iv heart failure (hf) confirmed left ventricular systolic dysfunction with left ventricular ejection fraction (lvef) \<40% as assessed by noninvasive imaging studies such as echocardiography or cardiac mri within the last 6 months admitted with decompensated heart failure and almost ready for clinical discharge 3. patient must have had adequate therapy for acute decompensated hf (heart failure) episode prior to enrollment exclusion criteria: 1. patients with acute coronary syndrome 2. resynchronization therapy initiated less than 90 days prior to enrollment 3. (lvad) left ventricular assist device or heart transplantation expected within the next 3 months 4. patients on hemodialysis or end stage renal disease (esrd) 5. patients with serum albumin less than 3 g/dl or evidence of liver cirrhosis 6. patients with uncontrolled arterial hypertension (systolic blood pressure \> 180 or diastolic blood pressure \>110) 7. patients with severe valvular heart disease 8. patients with acute myocarditis 9. patients with serum creatinine \>3.0 mg/dl or bun \>70 mg/dl 10. patients with hemodynamic instability or significant active arrhythmias 11. patients currently on intravenous inotropic therapy or those that have received inotropic therapy within the last 24 hours prior to study enrollment 12. patients currently on cyp3a inhibitors, or patients that have taken cyp3a inhibitors within 3 months prior to enrollment 13. patients with ongoing ischemia 14. patients who have had a myocardial infarction within 30 days prior to study enrollment 15. patients who are pregnant, nursing, or planning to become pregnant during the study period
hyponatremia in the elderly: benefit from a change in drug therapy?

Conditions: Hyponatremia

Summary: mild hyponatremia is the commonest electrolyte imbalance in the older population. recently, association between hyponatremia and bone fractures in the ambulatory elderly has been shown. mild chronic hyponatremia is causing falls and lead to hospitalisation because of attention deficit. symptoms related to hyponatremia can be very subtle and difficult to detect clinically. twenty elderly patients, retirement homes residents, with serum sodium \< 135meq/l will be included. they will be randomised. the physician will review the drug treatment of ten patients in coordination with the opinion of pharmacologists. drug treatment for ten other patients wil remained unchanged during the three months of inclusion. useful elements of the medical records of patients randomized to the experimental arm will be forwarded to the pharmacovigilance regional center for opinion pharmacologist. the notice, subject to the attention of physician of retirement homes, give rise to a therapeutic approach towards the patient. it will be followed by weekly monitoring of serum sodium for 4 weeks to evaluate the impact of the intervention. thus, the effectiveness of medical intervention will be evaluated by an objective biological criteria: serum sodium in the fourth week. secondary endpoints will evaluate the duration of normalization of serum sodium and check the interest of correcting hyponatremia to improve postural capacities and eventually reduce the number of falls in the medium term (three months).


Eligibility criteria:
inclusion criteria: * patient over 65 years resident of dependent elderly * plasma sodium \<135 mmol / l less than a week, confirming earlier hyponatremia within a week to three month agreement given after patient information exclusion criteria: * venous system does not allow sampling - patient not taking medication-dementia

Keywords: hyponatremia; sodium level falls gait elderly
proof of concept study of cognitive improvement in patients with alzheimer's disease

Conditions: Alzheimer Disease

Summary: the purpose of this study is to demonstrate that azd3480 improves cognition in patients with mild or moderate alzheimer's disease, to assess the safety and tolerability of zad3480 and to define the optimal dose(s) to be used in future trials.


Eligibility criteria:
inclusion criteria: * provision of informed consent from patient and caregiver * clinical prognosis of probable alzheimer's disease * patient must have a caregiver visiting the patient at least three times weekly exclusion criteria: * significant neurologic disease or dementia other than alzheimer's disease * major depressive disorder, other major psychiatric disorder * use of acetylcholinesterase inhibitor or memantine for treatment of alzheimer's disease within 8 weeks prior to enrollment * impaired vision and/or hearing making cognitive testing difficult

Keywords: dementia alzheimer type alzheimer disease